J&J’s Dapoxetine Has Sound Safety Profile, But Will FDA Be Satisfied?

Johnson & Johnson's investigative short acting selective serotonin reuptake inhibitor dapoxetine produced no reports of suicidality in Phase III trials for premature ejaculation